Showing results (1-10 of 92) with videos related to
Sort By:
Pageof 10
International Journal of Oncology|April 14, 2000
Cell cycle control as a basis for cancer drug development (Review)E R McDonald, W S El-DeiryCancer Research|May 15, 1996
Repair Defect in p21 WAF1/CIP1 -/- human cancer cellsE R McDonald, G S Wu, T Waldman, et al.Current Opinion in Oncology|January 1, 1997
Role of oncogenes in resistance and killing by cancer therapeutic agentsW S el-DeiryCell Death and Differentiation|November 1, 2001
Insights into cancer therapeutic design based on p53 and TRAIL receptor signalingW S El-DeiryMolecular Therapy : the Journal of the American Society of Gene Therapy|August 10, 2000
The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosisR D Meng, E R McDonald, M S Sheikh, et al.The Journal of Biological Chemistry|March 30, 2001
Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signalingE R McDonald, P C Chui, P F Martelli, et al.Oncogene|March 6, 1997
Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting regionK Somasundaram, W S El-DeiryOncogene|April 25, 2000
Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding siteR Takimoto, W S El-DeiryPageof 10